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EXPOSURE OF 3D ORGANOTYPIC VAGINAL TISSUES TO SEMEN 
INDUCES EXPRESSION OF THE CHEMOKINE MCP-1, BUT DOES NOT 
ALTER TISSUE INTEGRITY 
 
SUBHA SINGH 
ABSTRACT 
      Studies using cell lines indicate that human semen induces inflammatory 
changes in vaginal epithelial cell cultures, which may promote HIV transmission.  Since 
the normal human vagina is differentiated into multiple cell layers, we conducted a study 
to determine the effect of semen on EpiVaginal™, a 3-D organotypic differentiated 
vaginal tissue model.  We measured the upregulation of inflammatory cytokines by 
Luminex assay and microarray technology, and tissue integrity by histology and 
transepithelial electrical resistance (TEER) assessments. We used three multilayered 
differentiated EpiVaginal™ models: VEC-FT, which contained both epithelium and 
fibroblast layers; VEC-PT, which is comprised of differentiated epithelium only, and 
VLC, which has a normal epithelium in addition of fibroblasts and Langerhans cells. We 
hypothesized that semen is not toxic to the EpiVaginalTM tissue, which is 
morphologically similar to native vaginal mucosa, and does not induce a 
proinflammatory response. We found that semen and/or seminal plasma did not induce 
the expression of proinflammatory cytokines, but did significantly upregulate the 
expression of MCP-1, a chemokine that can attract HIV target cells such as CD4+ T cells 
and macrophages. We believe this research closes an important gap in understanding the 
	vi	
impact of semen on vaginal epithelium cells by showing that semen does not have a 
broad proinflammatory effect on intact fully differentiated human vaginal tissues, but 
may induce the expression of MCP-1.   
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INTRODUCTION 
The Lower Female Genital Tract  
The lower female genital tract (LFGT) consists of the vagina and cervix 
(Beckmann 2010). The LFGT is a unique environment that is believed to be the initial 
site of Human Immunodeficiency Virus (HIV) infection following intercourse in women. 
The epithelial layer of the LFGT provides a mechanical barrier, as well as an 
immunological barrier to substances, secretions and pathogens within the vaginal lumen. 
It is the first line of defense against pathogens, such as HIV and Herpes Simplex Virus) 
(Anderson et al. 2014).  
Structure and Function of the Human Vagina 
The vaginal mucosa is a multilayered stratified squamous epithelium, which rests 
on the lamina propria (LP) (Anderson et al. 2014). Compared to the upper genital tract, 
which is a monolayer of columnar epithelial cells with tight junctions, the vaginal mucosa 
is lined with stratified squamous cells (Anderson et al. 2014). The boundary between the 
vagina and endocervix, known as the cervical transformation zone, is the most vulnerable 
to pathogen invasion with high counts of T cells and antigen presenting cells (APCs) 
(Anderson et al. 2014). The immune cells in the vagina, such as CD4+ T cells, dendritic 
cells and macrophages are predominantly located in the LP; except for Langerhans cells, 
immune cells are rarely found in the upper layers of the tissue (Pudney et al. 2005; 
Hladik and Hope 2009).  
The superficial layer of the human vaginal epithelium, known as the stratum 
corneum (SC), forms an interface between the host and environment. This layer is 
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comprised of dead flattened cells that have been cornified—they lack nuclei, intracellular 
organelles and functional DNA/RNA and do not have many cell-to-cell junctions 
(Anderson et al. 2014). Vaginal basal and super-basal epithelial cells include a number of 
cytokeratins, transglutaminase-1 and transglutaminase-3, caspase 14 and filaggrin 
(Anderson et al. 2014), but do not form keratin bundles that are indications of keratinized 
epidermal epithelia (e.g. skin) (Bragulla and Homberger 2009). Despite the lack of 
keratinization, it is an effective mechanical barrier against luminal secretions and 
pathogens (Hladik and Hope 2009) (Figure 1).  
The role of the epithelial surface is to provide an interface that separates the 
individual from the environment. Epithelial intercellular junctions maintain the integrity 
and organization of epithelia by regulating molecular and cellular traffic and by providing 
a physical barrier to pathogen infiltration and infection. Studies have shown that the 
structure of tight junctions can change in response to stimuli, such as inflammatory 
mediators and pathogen invasion (Gorodeski 2007). There are three major types of cell-
cell structural adhesions that are present between epithelial cells: tight junctions, adherens 
junctions, and desmosomes (Langbein et al. 2002; Marchiando et al. 2010). Tight 
junctions are composed of transmembrane proteins that connect across the intercellular 
space and create a seal to restrict molecules from diffusing across the epithelial cells 
(Langbein et al. 2002, Meng and Takeichi 2009). Tight junctions are comprised of a 
network of intermembrane fibrils of transmembrane proteins containing occludin, 
claudins, and junctional adhesion molecules (JAMs) (Langbein et al. 2002). Adherens 
junctions connect actin filaments from cell to cell to form an adhesion belt located below 
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the tight junctions (Marchiando et al. 2010; Green and Simpson 2007). Desmosomes 
connect keratin intermediate filaments from cell to cell to form a structural framework of 
great strength (Marchiando et al. 2010; Gorodeski 2007). The transcellular component of 
adherens junctions is comprised of epithelial cadherin (E-cadherin) dimers, anchored to 
the cytoskeleton via vinculin and α and β catenin (Meng and Takeichi 2009). The 
desmosomal adhesion proteins JAM3 (JAM-C), desmoglein, and desmocollin are 
anchored to intermediate filaments via a scaffolding network of plakin and armadillo 
proteins (Green and Simpson 2007). 
Hormones can also have an effect on tight junctions by degrading the junctions 
between the cells and making it more susceptible for virus to enter the epithelial layer. 
When human cervical-vaginal epithelial and endocervical cells were treated with ethylene 
glycol tetraacetic acid (EGTA) it blocked the acidification of the luminal surface and 
stimulated a decrease in acidification at the contraluminal surface of the tissue, indicating 
that the tight junctions are necessary for maintaining luminal acidification (Gorodeski et 
al. 2005). To further define the molecular structure of the intercellular junctions, select 
junction molecules were localized in the endocervical, ectocervical, and vaginal 
epithelium by fluorescent immunohistology. The most apical layers of the ectocervical 
and vaginal stratified squamous epithelium did not contain cell-to-cell adhesions and 
were permeable to IgG. The suprabasal and basal epithelial layers in ectocervical and 
vaginal tissue contained the most robust adhesions. Molecules characteristic of 
exclusionary junctions were detected three to four cellular layers below the luminal 
surface and extended to the basement membrane (Blackewicz et al. 2011).  
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The Effect of Hormones on the LFGT 
Reproductive hormones affect the vaginal epithelium in several ways. Hormones 
can affect the function and structure of the vaginal tissue in women (Patton et al. 2000). 
The structure differs based on the age, which can be divided into pre-pubertal, 
reproductive and postmenopausal stages. During childhood, progesterone and estradiol 
are both present at low levels (Venkatesh and Cu-Uvin 2013). Young girls before puberty 
have a thin vaginal thin epithelium with only basal and parabasal layers (Colvin and 
Abdullatif 2013). During the reproductive years, the vaginal epithelium thickens (25–40 
cell layers thick) and develops a cornified layer. It is also during this time that there is a 
rise in secretions of luteinizing hormone, followed by an increased secretion of estradiol 
(Venkatesh and Cu-Uvin 2013). Production of sex hormones varies with ovarian activity.  
There are three main types of sex hormones that are produced during the reproductive 
LP	 LP	B	
B	
SC		SC		
L	 L	
Figure 1. MatTek EpiVaginalTM tissue vs. Ectocervical Tissue  
Visualization of the MatTek EpiVaginal™ Full Thickness tissue and human 
ectocervical explant tissue with Hemotoxylin stain. A) VEC-FT showing the lamina 
properia (LP), the basal layer (B), the stratum corneum (SC) and Lumen (L). B) 
Ectocervical tissue showing the lamina properia (LP), the basal layer (B), the stratum 
corneum (SC) and Lumen (L). 
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age: estrogens, progestins and androgens. Hormonal fluctuations in the menstrual cycle 
include increasing 17β-estradiol (E2) concentration, but low progesterone plasma 
concentrations in the follicular phase, and high plasma E2 and progesterone 
concentrations in the luteal phase (Annechien et al. 2005). After menopause the ovaries 
no longer produces high levels of estrogen and progesterone (P) and the vaginal 
epithelium thins (Thompson et al. 2001), which can increase the possibility of 
transmission of sexual diseases and inflammation  (Venkatesh and Cu-Uvin 2014).  
Reproductive hormones also affect vaginal microflora, which play an important 
role in innate immunity. The healthy vagina of reproductive aged women is normally 
colonized with lactobacilli species that produce lactic acid, maintaining a natural low pH 
antimicrobial environment (Hearps et al. 2017). Lactobacilli also exert anti-inflammatory 
effects in vaginal tissue (Hearps et al. 2017). Lactobacilli metabolize glycogen, which is 
produced by vaginal epithelial cells under the influence of estrogen (Hearps et al. 2017).    
The Effects of Reproductive Hormones on the Sexual Transmission of Pathogens 
Several studies have investigated the effects of reproductive hormones on vaginal 
infection in animal models. In a mouse model, estrogen and progesterone were used to 
determine the effects of hormones on susceptibility to Candida albicans infection (Fidel 
et al. 2000). The results of this study showed that estrogen sustained C. albicans infection 
and reduced the innate immune response of epithelial cells against Candida. 
Progesterone, on the other hand, had no effect (Fidel et al. 2000).  
The stage of the menstrual cycle or the presence of exogenous estrogen and 
progesterone affects susceptibility to many sexually transmitted infections (STIs) in both 
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humans and animal models. In a mice model, it was determined that they were most 
susceptible to infection by Neisseria gonorrhoeae when endogenous estrogen levels are 
highest at the earliest state. Progesterone increased the mortality rate of mice if they were 
infected with Herpes Simplex Virus 2 (HSV-2). Studies of HSV-2 infection showed mice 
are mostly susceptible to infection during the early to late periods of dioestrus. An 
increase in estradiol treatment in the mouse model helped prevent infection of 
Mycoplasma hominis and Ureaplasma urealyticum; however, if the mouse were 
pretreated with progesterone it increased susceptibility to infection with Mycoplasma 
pulmonis and Chlamydia muridarum (Beagley and Gockel 2003). 
To determine the efficacy of topical estrogen in preventing Simian 
Immunodeficiency Viruses (SIV) vaginal transmission, a non-human primate model of 
HIV vaginal transmission was used to assess vaginal estriol cream in ovariectomized 
macaques. The results showed that vaginal estriol had no effect on the level of luteinizing 
hormones. The data demonstrated that topical vaginal estriol could strongly protect 
against SIV, while having no detectable systemic effect. It has been proposed that 
estradiol cream may prevent HIV transmission in women, especially after menopause. 
(Smith et al. 2004).  
Ex vivo and In vitro Models of HIV Transmission  
Various in vitro models have been used to study how HIV infects the vaginal 
epithelium. Explants from either biopsy or post-operative vaginal or cervical tissue from 
healthy premenopausal women are often used for HIV infection studies. These explants 
retain their normal immune populations and various studies have shown that explants can 
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be infected with HIV (Miller and Shattock 2003). When using cervical tissue there is a 
limited amount of clinical information that is available for the researcher about the tissue 
sample, for example if the patient was on hormonal treatment before the surgery. The 
hormonal status of the women, can impact the thickness of the tissue and the research 
results. Prior or current infections could have changed the composition of immune cells 
present in the tissue. The size of explant tissue also limits the replicability of ex vivo 
assays. Frequently, Betadine, a microbicide disinfectant, is used on the vaginal cavity and 
ectocervix before a hysterectomy leading to the death of normal vaginal flora, affecting 
the results of the experiments. In ex vivo culture, the tissue structure deteriorates making 
the epithelial barrier more exposed to HIV target cells causing a proinflammatory 
response. Though there are steps to prevent the degradation of tissue after biopsy is 
obtained, it is not 100% effective and human error can easily occur (Anderson et al. 
2010). Thus EpiVaginal™ tissue models are more reliable to represent the normal human 
vaginal tissue structure.  
Immortalized cell lines have been developed from normal human vaginal 
(Vk2/E6E7), ectocervical (Ect1/E6E7) and endocervical (End1/E6E7) epithelium by 
transfection with the human papillomavirus 16/E6E7 gene (Fichorova et al. 1997). They 
offer several advantages: they are cost effective, easy to use, provide an unlimited supply 
of material, and bypass ethical concerns associated with the use of animal and human 
tissue. Cell lines also provide a pure population of cells, which is valuable since it 
provides a consistent sample and reproducible results. However, there are some 
disadvantages to using cell lines in place of primary cells. Cell lines should display and 
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maintain functional features as close to primary cells as possible, though sometimes this 
is hard to determine because the functions of the primary cells are not entirely 
understood. Since cell lines are genetically manipulated this may alter their phenotype, 
native functions and their responsiveness to stimuli. Serial passage of cell lines can 
further cause genotypic and phenotypic variation over an extended period of time and 
genetic drift can also cause heterogeneity in cultures at a single point in time. Therefore, 
cell lines may not adequately represent primary cells and may provide different results 
(Kaur and Dufour 2012).  
A human differentiated vaginal tissue model, EpiVaginal™, was developed by 
MatTek Corp. Ashland, MA USA. The tissue is reconstructed from normal human 
vaginal cells and is designed to be very similar to native tissue (Ayehunie et al. 2015 and 
2011). Histologically, EpiVaginal™ has a 3D stratified structure that contains basal, 
suprabasal, intermediate, and superficial cell layers (Ayehunie at al. 2006) (Figure 1). 
Cells, which form the superficial SC layer, become enucleated and the amount of 
glycogen in the cells increases in the apical layer, which is similar to native vaginal-
ectocervical tissue. Tight junctions are intact and the tissue expresses the differentiation 
markers, such as cytokeratins 13 and 14, similar to native tissue (Ayehunie et al. 2006). 
The EpiVaginal™ tissues can be cultured for extended amounts of time (2–3 weeks), and 
up to 50,000 highly reproducible tissues can be reconstructed from a single explant 
(Ayehunie et al. 2006). This ability allows researchers to perform multiple experiments, 
improving the reproducibility of results (Ayehunie et al. 2006). Current research results 
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show that the EpiVaginal™ tissue is a good model for pre-clinical screening of vaginal 
products (Ayehunie et al. 2006).  
EpiVaginal™ tissues express hormone receptors, and treatment with E2 increased 
thickness of the vaginal epithelium and Transepithelial Electrical Resistance (TEER) 
(Ayehunie et al. 2015). In contrast, the addition of progesterone to the tissue decreased 
the thickness of the epithelium and TEER (Ayehunie et al. 2015). This change to the 
thickness of the epithelium could either enhance or decrease the barrier function of the 
tissue layers.  
Semen Composition and Cytokines 
Semen is a biologically active organic fluid that contains spermatozoa, immature 
germ cells, leukocytes and a cell-free fraction called seminal plasma. Seminal plasma 
consists of a mix of nutrients, immune factors, and enzymes (Garcia-Closas et al. 1999). 
One function of seminal plasma is to create an alkaline-buffered zone in the vagina. A 
neutral pH in the vagina is needed for the sperm to stay alive and motile (Garcia-Closas 
et al. 1999). It also helps with the coagulation of the ejaculate and creates a sperm depot. 
On average the pH of semen is neutral, 7.2 to 7.8 (Garcia-Closas et al. 1999).  
Semen from HIV-infected men can contain variable amounts of infectious HIV. 
Previous studies have shown that the infectiousness of semen can be influenced by 
several factors, including systemic viral load, concomitant genital tract infections and 
inflammation (e.g. GC and HSV-2), HIV disease stage, and use of antiretroviral drugs  
(Thurman and Doncel 2011). In women, pre-existing inflammation caused by infections 
such as Bacterial vaginosis, can disturb the lining of the layers and interfere with the 
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innate antimicrobial activity (Thurman and Doncel 2011; Louissaint et al. 2012), 
predisposing women to HIV infection. In the LFGT semen can increase the pH of the 
vaginal fluid for up to two hours after exposure, providing a less acidic environment that 
allows the HIV to survive (Thurman and Doncel 2011; Fox et al. 1973).  
Effects of Semen on HIV Transmission 
Literature review suggests semen has a proinflammatory effect on vaginal mucosa 
(Sharkey et al. 2012). It was determined that some cytokines were upregulated, while 
others were downregulated when semen was exposed to epithelial cells in vitro. Politch et 
al. (2007) determined that semen contained high concentrations of cytokines, such as 
TGF-β, IL-7, MCP-1 and IL-8 (>1000 pg/ml), while IL-1α, IL-1β and IL-6 were found in 
low concentrations (<150 pg/ml). The authors concluded that healthy semen had a broad 
range of cytokine concentrations, which may also impact the amount of inflammation 
experienced by vaginal epithelial cells (Politch et al. 2007). Sharkey et al. (2012) showed 
an increase of leukocytes in the human cervix after sexual intercourse. Their research 
demonstrated that when vaginal epithelium is exposed to seminal fluid the leukocyte 
populations have an ‘inflammatory-like’ response, resulting in penetration through the 
epithelial layer and up to several millimeters deep in the stroma of the ectocervix. The 
researchers noted a consistent increase in cytokines IL-1α, IL-6 and IL-8 in the cervical 
tissue in women after condomless sexual intercourse when compared to use of condoms 
for protected sexual intercourse or abstinence (Sharkey et al. 2012).  
There is also evidence that semen or seminal plasma may have a role in the 
efficiency of HIV transmission. Factors that tend to have an inhibitory effect in seminal 
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plasma or semen resulting in anti-HIV activity are, cationic polypeptides (Martellini et al. 
2009), and a potent inhibitor that attaches to the DC-specific intercellular adhesion 
molecule 3-grabbing non-integrin (DC-SIGN) (Sabatte et al. 2007).  
In contrast, there is also evidence that semen or seminal plasma may also have an 
enhancing role in the transmission of HIV. A molecule in semen called semen-derived 
enhancer of virus infection (SEVI) is comprised of amyloid fibrils formed by prostatic 
acidic phosphatase fragments.  These fibrils are negatively charged and increase the 
attachment of to HIV to target cells, such as CD4+ T lymphocytes and dendritic cells 
(Munch et al. 2007).  SEVI research is focused on the formation of SEVI fibrils that are 
derived from synthesis PAP peptides under in vitro conditions with prolonged agitation at 
high temperature and with significantly higher peptide concentrations, which may not 
reflect what happens in nature. There have been studies that have found fibril amyloids in 
human semen, however the seminal fluid itself may alter the formation and structure of 
these fibrils. In a study that studied the formation of these fibrils in the presence of 
macromolecular crowding agents resulting in shorter fibrils being formed, which were 
considered to be in the intermediate state, was more efficient binding to HIV virus. 
However these results have not been duplicated in in vivo experiments (Gour et al. 2016) 
and thus other factors need to be taken in consideration when looking at results between 
in vivo and in vitro models (Gour et al. 2016).  
Another study demonstrated that R5- and X4-HIV1 strains activated complement 
pathways that generated a C3 cleavage fragment that enhanced HIV infection (Bouhlal et 
al. 2002). TGF-β and 19-OH-prostaglandin E (PGE) that are present in high 
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concentrations in semen cause an immunosuppressive response in the innate and adaptive 
immune system that could facilitate HIV transmission (Quayle et al. 1989; Kelly 1995). 
Various studies have described an inflammatory response of vaginal epithelial cells when 
exposed to semen (Thurman and Doncel 2011), and since inflammation recruits and 
activates HIV target cells such as CD4+ T lymphocytes and macrophages, it has been 
proposed that semen exposure enhances HIV transmission. However, the response of 
EpiVaginalTM to semen or seminal plasma in vitro has not been described. Understanding 
whether the EpiVaginalTM model response is similar or different than that seen with cell 
lines and ex vivo tissue is important in assessing the feasibility and limitations of using 
EpiVaginalTM for various mucosal studies including HIV and other STIs, and 
nonpathogens, such as vaginal products. 
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Objective and Specific Aims 
 
Deposition of semen within the vagina is a physiological event during sexual 
intercourse. Determining the effect of semen and seminal plasma (SP) on vaginal mucosa 
is an important aspect of evaluating the pathogenesis of various STIs. Most studies have 
used explant tissue or monolayers from immortalized cell lines to determine effects of 
seminal plasma on cytokine production in the vaginal epithelium. However, there are 
several limitations to these models, namely, inter-donor variability, tissue degradation in 
case of explant tissue and histologically dissimilar structure when using cell line 
monolayers. There is a need to establish an in vitro model system to further the field of 
STI research and mucosal immune response. In the present study, we therefore proposed 
to evaluate the effect of semen and seminal plasma on the EpiVaginalTM model. 
 
Hypothesis: Semen or seminal plasma is not toxic to the EpiVaginalTM tissue, which is 
morphologically similar to native vaginal mucosa, and does not induce a 
proinflammatory response.  
 
Aim 1: Evaluate whether semen or seminal plasma treatment alters the morphology or 
tissue integrity of EpiVaginalTM tissue. 
Aim 2: Determine whether semen or seminal plasma causes inflammation of 
EpiVaginalTM tissue. 
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MATERIALS AND METHODS 
 
EpiVaginal™ Tissue Model 
We have previously described the use of EpiVaginal™ tissue (Ayehunie et al. 
2015), which is commercially available for purchase from MatTek Corporation (Ashland, 
MA). EpiVaginalTM tissue is a 3D organotypic tissue cultured from normal human 
derived vaginal epithelial cells and differentiated using a proprietary medium. Three 
different types of epithelial tissue were obtained. Partial thickness EpiVaginal™ tissue 
(VEC-PT) is comprised of epithelial cells grown on a basement membrane with no 
lamina propria. Full thickness EpiVaginal™ tissue (VEC-FT) is epithelial cells grown on 
a basement membrane with a lamina propria. While, full thickness EpiVaginalTM tissue 
with Langerhans Cells (VLC) is similar to VEC-FT but contains immunocompetent 
Langerhans cells. Medium used for tissue culture is proprietary and used per 
manufacturer’s instructions.  
Semen Samples  
Semen samples were collected from normal male donors by masturbation into 
sterile specimen containers, and processed within one hour of collection. For our 
experiments the seminal plasma, seminal leukocytes and motile spermatozoa were 
separated using ISolate® gradients (Irvine Scientific, Santa Ana, CA) per manufacturer’s 
protocol. For the seminal plasma (SP) and semen treatment, pooled SP or whole semen 
from 2-3 donors were used with 50µL per tissue applied to the apical layer.  
		 15	
Leukopaks 
Leukopaks were obtained from New York Biologics Inc. (Southampton, NY). It is 
an enriched leukapharesis product, which contains white blood cells, red blood cells 
(RBCs), platelets and plasma. Leukopaks were processed to obtain RBCs as noted below. 
Ethics Statement  
This study was approved by the Boston University Medical Center (BUMC) 
Institutional Review Board (IRB). Written informed consent was obtained from all 
recruited subjects in advance. Subjects were self-reported healthy volunteers from 
BUMC. All samples were de-identified prior to cell isolation in the laboratory. 
Hemolysis of RBCs 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by 
using the Ficoll-Paque method, per manufacturer’s protocol and reserved for other 
experiments. The red blood cell (RBC) pellet was washed twice with 30mL of PBS. After 
the final wash, RBCs were re-suspended in 30 mL of PBS and distributed in six 15 mL 
conical tubes and centrifuged for 10 minutes at 1500 rpm. The supernatant was then 
discarded. 10-fold serial dilution of N-9 from 0.2% to 0.0002% was done and added to 
RBC pellets. RBCs incubated in EpiVaginalTM medium served as the negative control 
and 1% Triton X was the positive control. The tubes were then incubated at room 
temperature for 20 minutes. The samples were centrifuged and supernatant discarded. A 
RBC smear was done for the pelleted cells on a glass slide. The smears were visualized at 
10x using a Nikon Diaphot microscope (light microscope). 
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Treatment of EpiVaginalTM Tissues  
EpiVaginalTM tissues were obtained from MatTek corp. and were equilibrated 
overnight in an incubator at 37oC. The following day, the tissue was transferred to 
another 24 well plate in which fresh-pooled seminal plasma (SP) or pooled whole semen 
was added apically (50µl) and 400µl of Medium was added to the basal compartment. 
50µl of 0.2% Nonoxynol 9 (N9) (Ortho Options Conceptrol, Madison, NJ) was added to 
the apical compartment as a positive control, as previously described (Hjelm, 2010). 
Tissues were either treated with SP, semen, 2hr pulsed 100% SP or 2hrs pulsed 100% 
semen, and followed by three PBS washes with subsequent incubation in Medium. 50µl 
of volume was used for each treatment or medium condition for the apical layer. The 
treated tissues were incubated for an additional 24 hours at 37oC. During the incubation 
period, basal (100µl) supernatants were collected from each well at 2hrs, 8hrs, and 24hrs. 
Apical (50µl) supernatants were collected at 24 hours. The supernatants were stored at -
80oC till further processing. Treatments were run in triplicates, and in each experiment 
different samples were analyzed concurrently. At each time point of 2, 8 and 24 hours 
one tissue from each treatment or control group was either fixed with 10% formalin for 
histology or stored in TRIzol (ThermoFisher Scientific, Waltham, MA). Tissues stored in 
TRIzol were stored at -80oC till further processing.  
Histology  
EpiVaginalTM tissues fixed in 10% formalin were embedded in paraffin wax 
(Leica Biosytems, Wetzlar, Germany). Sections of tissue were cut (5-7µm thick), 
collected on glass slides, de-waxed, processed through graded ethanols (Anatech LTD., 
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Battle Creek, MI) and then stained with hematoxylin (Dako, Santa Carla, CA). The tissue 
sections were imaged using a Nikon Diaphot microscope.  
Tissue Viability Measured by TEER 
Transepithelial Electrical Resistance (TEER), a measure of intercellular junctions 
and tissue integrity, was measured using an EVOM volt-ohmmeter equipped with an 
Endohm electrode chamber (World Precision Instruments, Sarasota, Florida) at 2hrs, 
8hrs, and 24hrs after treatment exposure. Low TEER represented a decrease in tissue 
integrity.  
Multiplex Luminex™ Protein Assay 
The concentration of cytokines secreted by VEC tissue in basal compartment as a 
response to treatment was assessed by using a customized ProcartaPlexTM Assay 
(ThermoFisher Scientific, Waltham, MA). The samples were processed per 
manufacturer’s protocol. Briefly, 50µl of basal tissue culture supernatants and standards 
were added to 25µl of washed antibody magnetic beads in each well of a 96 well plate. 
This was followed by a two-hour incubation with shaking in the dark at room 
temperature. The plate was washed three times and 25µl of detection antibody was added 
to each well. The plate was sealed and incubated on a shaker for 30 minutes at room 
temperature in the dark. The plate was washed three times and 50µl of streptavidin-PE 
was added to each well. The plate was sealed and incubated on a shaker for 30 minutes at 
room temperature in the dark followed by washing. Reading buffer (120µl) was added to 
each well and the plate was shaken for five minutes at room temperature. Samples were 
analyzed on a Bio-Plex 200 Luminex reader and analysis performed using the Bio-Plex 
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Manager software (Bio-Rad, Hercules, CA). The cytokines quantified were IL-1α, IL-1β, 
IL-1RA, IL-8, IL-6, MCP-1.  
Microarray 
 Affimetrix Genechip Human Gene 1.0 ST arrays were used to analyze RNA 
isolated from VEC-FT tissues treated with Medium, SP or 2hr pulsed SP. For each 
treatment group, 2 separate tissues were pooled and homogenized in TRIzol. The RNA 
samples were processed by the Boston University Microarray Core for messenger RNA 
(mRNA) extraction and microarray analysis. Data analysis was performed using the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) 
bioinformatics resource (Da et al. 2008). Changes of >2-fold in mRNA expression were 
considered significant. Genes of interest were additionally identified and heat maps were 
created to evaluate for significant differences. 
Quality Control  
For the EpiVaginalTM tissues, quality control (QC) was completed by MatTek 
Corporation as published on their website. All tissues used for these experiments passed 
the QC test. Quality Control was also completed for the Bio-Plex 200 Luminex plate 
reader by using a performance verification kit and calibration kit (Luminex Corporation, 
Austin, TX) before quantification.  
Statistical Analysis 
For comparisons between different treatment groups, data was analyzed and 
plotted using GraphPad Prism version 7.01 (La Jolla, CA, USA) software. Data values 
were compared between treatment groups to Medium alone. A two-way ANOVA with 
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Tukey’s multiple comparisons post-hoc test was used for analyzing data.  A significance 
level of 0.05 was set for all statistical tests. Values were reported with means ± SEM. 
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RESULTS 
 
Histology of Treated EpiVaginalTM Tissue   
  
Histological assessment of EpiVaginalTM tissue was done for evaluation of tissue 
morphology and integrity over a time course of 8 and 24 hours (Figure 2). VEC-FT 
tissues showed no change in morphology at 8 or 24 hours irrespective of the treatment 
condition.  Figure 2 demonstrates preserved stratum corneum (SC), basal (B) and 
parabasal cell layers over a lamina propria (LP) for all tissues. 0.2% N9, which served as 
the positive control also showed preserved tissue morphology. We therefore evaluated 
RBC hemolysis as a measure of N9 activity. 
RBC hemolysis as a qualitative dose response to varying concentrations of N9, a 
detergent, was assessed. 0.2% N9 induced hemolysis whereas higher dilutions of N9 did 
not cause hemolysis at 20 minutes (Figure 3).  
Processing of VEC-PT and VLC tissue sections was technically challenging and 
we were unable to draw definitive conclusions from subsequent hematoxylin staining.  
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8	Hours	 24	Hours	
Figure	2.	Hematoxylin	Stained	Cross-sections	of	VEC-FT		Preserved	tissue	morphology	was	noted	for	all	treatment	conditions.	A)	Medium-control	8	hours	B)	0.2%	N9	8	hours	C)	2	hour	pulsed	SP	8	hours	D)	SP	8	hours	E)	2	hour	pulsed	semen	8	hours	F)	100%	semen	8	hours	G)	Medium-control	24	hours	H)	0.2%	N9	24	hours	I)	2	hour	pulsed	SP	24	hours	J)	SP	24	hours	K)	2	hour	pulsed	semen	24	hours	L)	100%	semen	24	hours.		L=	Apical	lumen,	SC=	stratum	corneum,	B=	basal	cell	layer,	LP=	lamina	propria.				
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Effect of Semen and Seminal Plasma on TEER 
 
 TEER measurements were done for all three types of EpiVaginalTM tissues over a 
time course of 2, 8 and 24 hours. VEC-FT tissues showed no significant difference in 
TEER values between Medium, 2 hour pulsed SP, 100% SP, 2 hour pulsed semen and 
100% semen treated tissues over the course of treatment (Table 1A). At 8 hours, VEC-
FT tissue treated with 100% SP had a significantly lower TEER (p <0.05) when 
compared to the Medium control. However, there was no significant decrease in TEER of 
100% SP treated tissue at 8 hours when compared to 2 hours or 24 hours. 0.2% N-9 
treated tissues also had significantly lower TEER value at all three time points (p 
<0.0001) when compared with Medium treated tissues (Table 1 and Figure 4). 
Similarly, for VEC-PT and VLC tissues there was no significant difference in TEER 
values between the various treatment groups (Table 1B and Figure 4).  
	
A	 B	 C	
Figure	3.	0.2%	N9	Causes	Hemolysis	of	Red	Blood	Cells	within	20	minutes	Representative	images	of	RBCs	(arrows)	show	intact	cells	when	treated	with	Medium	(A)	and	0.0002%	N9	(B).	100%	hemolysis	of	RBCs	is	noted	on	treatment	with	0.2%	N9	(C).			
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Table 1: Summary of TEER (barrier function) values following topical treatment of 
EpiVaginalTM tissues at 2, 8 and 24 hours. (*p<0.05, **= p<0.0001) 
  
 
Table 1A:  
Duration of 
treatment 
VEC-FT 
Medium 
2hr 
pulsed 
SP 
SP 2hr pulsed semen Semen 0.2% N-9 
2 hours 2000 ± 0 2000±0 1648±352 2000±0 2000±0 576.8±146.1** 
8 hours 2000±0 2000±0 1305.8±351.6* 2000±0 1962.5±30.3 325.3±37.8** 
24 hours 2000±0 2000±0 1507±493 2000±0 1993.7±6.3 428.7±43.3** 
 
 
Table 1B: 
Duration 
of 
treatment 
VEC-PT VLC 
Medium 2hr pulsed semen Semen Medium 
2hr pulsed 
semen Semen 
2 hours 470.7±10.2 432±60.7 495.3±36.6 486±47.7 438±58.3 633±19.4 
8 hours 473±37.9 477.3±17.2 470±16.4 478.7±39.6 654±136.1 581.6±52.6 
24 hours 455±29.7 443±19.9 364.3±20.3 540.7±50.7 641±30 573.7±75.7 
		 24	
Figure	4.	TEER	values	for	VEC-FT,	VEC-PT	and	VLC	VEC-FT,	VEC-PT	and	VLC tissues were treated with Medium, 2 hour pulsed SP, 100% SP, 2 
hour pulsed semen and 100% semen for a total duration of 24 hours. Barrier function of the 
tissues was measured by TEER at 3 different time points (2, 8 and 24 hours). Each	data	point	represents	mean	of	triplicates ± SEM. *p<0.05	**p<0.0001.	 	
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Responsiveness of EpiVaginalTM Tissue to Semen and Seminal Plasma Treatment 
To evaluate whether pro/anti-inflammatory cytokines were secreted during 
treatment of EpiVaginalTM tissue with semen or SP, cytokine quantification of basal 
supernatants collected at 2, 8 and 24 hours was done by using a ProcartaPlex Mix&Match 
Human 6-plex custom kit (lot #172666000). Nonoxynol 9 (N9) was used as a positive 
control for inflammation. N9 treated VEC-FT tissues showed significant increase of IL-
1RA secretion at 2 (p < 0.01) and 8 hours (p<0.0001) (Table 2A), and IL-1α at 2 hours 
(p< 0.05) and 8 hours (p<0.0001) (Table 2B). VEC-FT pulsed for 2hr with SP or treated 
with 100% SP showed an increase in IL-1β at 24 hours (p <0.001, p <0.01, respectability) 
(Table 2C).  MCP-1 was transiently elevated at 2 hours for tissues pulsed for 2hr with 
semen (p<0.05) (Table 2F). IL-6 and IL-8 did not show any significant increase (Table 
2D, 2E) (Figure 5) with the various treatments. 
100% semen treated VEC-PT showed significant increase for cytokines IL-8  
(p <0.05) (Table 3E) and MCP-1 (p<0.0001) (Table 3F). Similarly, for VLC tissues 
treated with 100% semen, at 24 hours, there was a significant increase of MCP-1 
(p<0.01) (Table 3F). A lower concentration of N9 [0.002%] was used in treatment of 
VEC-PT and VLC tissue types and showed no significant difference in cytokine profile 
when compared to medium treated tissues (data not shown). 
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Table 2: Summary of Cytokines (pg/ml) for VEC-FT tissues after various 
treatments. 
Mean ± SEM values following topical treatment of EpiVaginalTM tissue (VEC-FT) at 2, 8 
and 24 hours (*p≤ 0.0444, **p≤0.0098, ***p≤0.0005, ****p≤0.0001) 
 
Table 2A: IL-1RA 
Duration of 
treatment 
VEC-FT 
Medium 
2hr 
Pulsed  
SP 
SP 
2hr 
Pulsed  
Semen 
Semen 0.2% N-9 
2 hours 9151.6± 923.7 
7588.8± 
467 
13326± 
1176.5 
6670.9± 
997.8 
6954.9± 
1591.3 
176469.2± 
34021.8** 
8 hours 18765.5± 2018.5 
17630.1± 
3961.7 
19179.7± 
3130 
21996.3± 
7648.1 
9276.8± 
848.5 
473268.9± 
127280.1**** 
24 hours 8449.9± 2853.6 
11072.8± 
1838.8 
10532.3± 
469.6 
6964.6± 
572.2 
7231.1± 
1386.8 
15661.6± 
1887.6 
 
Table 2B: IL-1α 
Duration 
of 
treatment 
VEC-FT 
Medium 2hr Pulsed SP SP 
2hr Pulsed 
Semen Semen 0.2% N-9 
2 hours 99.2±6.2 108.9±4 123±5.1 122.1±1.8 96.4±6.4 171.7± 37.8* 
8 hours 150.2±8.2 101.2± 22.8 
126.3± 
15.9 
111.7± 
15.4 56.6±12.2 
271± 
38.9**** 
24 hours 50.1±17.3 71.5±3 100.4±4.5 41.8±9.3 69.4±12.5 118.5± 11.2 
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Table 2C: IL-1β 
Duration of 
treatment 
VEC-FT 
Medium 2hr Pulsed SP SP 
2hr Pulsed 
Semen Semen 0.2% N-9 
2 hours 3.7±0.6 4±0.2 3.5±0.2 4.5±0.2 4.6±0.4 17.3±8.3 
8 hours 5.5±0.5 5±0.7 61±1.3 6.2±0.6 3.6±0.6 27.6±5.7 
24 hours 60±20.1 152.1± 39*** 
139.4± 
41.5** 83±17.2 
104.2± 
27.2 96.6±7.7 
 
Table 2D: IL-6 
Duration 
of 
treatment 
VEC-FT 
Medium 2hr Pulsed SP SP 
2hr Pulsed 
Semen Semen 0.2% N-9 
2 hours 1784.3± 462 
2382.4± 
429 
2290.6± 
675.8 
2743.2± 
141.6 
1638.6± 
336.5 
2491.2± 
402.1 
8 hours 2203± 558.3 
1560.3± 
275.4 
1976.7± 
421.6 
2296.3± 
402.3 
1153.9± 
242.2 
2706.8± 
351.1 
24 hours 348.8± 98 
596.5± 
79.2 
928.4± 
109 
469.8± 
69.5 
791.8± 
149 
207.6± 
48.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		 28	
Table 2E: IL-8 
Duration 
of 
treatment 
VEC-FT 
Medium 2hr Pulsed SP SP 
2hr Pulsed 
Semen Semen 0.2% N-9 
2 hours 2908.5± 403.1 
433.6± 
45.3 
4382.7± 
288.8 
3544.7± 
363.5 
2088.4± 
1994.4 
4191.2± 
520.4 
8 hours 4770.6± 948.6 
2188.9± 
1149.4 
2860.8± 
674.1 
2143.1± 
582.8 
735.5± 
227.7 
6275.2± 
1246.6 
24 hours 310.7± 122.5 
433.6± 
45.3 
704.8± 
115.5 
268.7± 
60.4 
472.6± 
107.1 
542.1± 
188.4 
 
Table 2F: MCP-1 
Duration of 
treatment 
VEC-FT 
Medium 2hr Pulsed SP SP 
2hr Pulsed 
Semen Semen 0.2% N-9 
2 hours 2351.2± 313.4 
3327.6± 
536 
3331.4± 
432.3 
3805.5± 
574.6* 
2216.5± 
343.8 
2829.5± 
448.1 
8 hours 2693.1± 314 
1510.2± 
413.9 
2013.3± 
294.7 
2325.2± 
216.1 
977.7± 
293.5 
2867± 
353.4 
24 hours 257.5± 98.9 
429.8± 
49.5 
646.8± 
53.2 
381.6± 
30.1 
435.8± 
140 
201.2± 
29.9 
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Table 3: Summary of Cytokines (pg/ml) for VEC-PT and VLC tissues after various 
treatments. 
Summary of Mean ± SEM values following topical treatment of VEC-PT and VLC at 2, 
8 and 24 hours (*p≤ 0.05, **p<0.01 and **** = p≤0.0001) (**p≤0.0057) 
 
Table 3A: IL-1RA 
Duration 
of 
treatment 
VEC-PT VLC 
Medium 2hr Pulsed Semen Semen Medium 
2hr Pulsed 
Semen Semen 
2 hours 88358.2± 11017 
54726± 
18460.7 
37119.5± 
18719.4 
60787.9± 
5762.8 
40676.5± 
4399.7 
36723.1± 
12934 
8 hours 164848.5± 73360.5 
51734.5± 
18042.4 
43870± 
6225.8 
61196.6± 
1944.6 
29532± 
1170.2 
21360± 
10927 
24 hours 190356.8± 32221.4 
87519.4± 
22116 
114908.7± 
16989.2 
94925±1 
2673.3 
41990.5± 
5900.1 
112350± 
56296.6 
 
Table 3B: IL-1α 
Duration 
of 
treatment 
VEC-PT VLC 
Medium 2hr Pulsed Semen Semen Medium 
2hr Pulsed 
Semen Semen 
2 hours 331.8±75.3 392.7±75.1 203.8±123.8 359±18.6 425.7±59.1 279.7±49 
8 hours 242.9±67.1 392.6±112 380.2±88.4 364.3±17.8 356.7±22.9 174.6±52.4 
24 hours 590.3±83.8 668.2±69.9 899.2±56.1 397.5±35.1 419.7±44.1 598.6±137.8 
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Table 3C: IL-1β 
Duration 
of 
treatment 
VEC-PT VLC 
Medium 2hr Pulsed Semen Semen Medium 
2hr Pulsed 
Semen Semen 
2 hours 22.2±6.1 13.1±3.8 15.6±4.5 2.7±2.0 13.2±3.8 4.8±4.1 
8 hours 11.8±5 18.8±11.4 9.9±3.2 10.9±2.1 10.9±2.1 0.8±0.1 
24 hours 8.9±4.1 4.7±2 19.8±0.01 6.8±3.6 6.9±3.5 17.6±4.5 
 
Table 3D: IL-6 
Duration 
of 
treatment 
VEC-PT VLC 
Medium 2hr Pulsed Semen Semen Medium 
2hr Pulsed 
Semen Semen 
2 hours 9.2±2.3 6.9±2.3 6.9±2.3 4.6±0 4.6±0 4.6±0 
8 hours 6.9±2.3 26.5±21.8 9.2±2.3 6.9±2.3 6.9±2.3 4.6±0 
24 hours 9.2±2.3 18.3±6.8 25.1±6.8 4.6±0 35.7±31.1 44±23.1 
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Table 3E: IL-8 
Duration 
of 
treatment 
VEC-PT VLC 
Medium 2hr Pulsed Semen Semen Medium 
2hr Pulsed 
Semen Semen 
2 hours 8797.2± 2468.9 
11107.5± 
1955.5 
5572.8± 
3730.1 
11707.4± 
492.5 
14093.9± 
2167 
8063.9± 
1733.1 
8 hours 5658.8± 3126.5 
10961.6± 
1895.3 
10801.4± 
2920.8 
11598.4± 
987.8 
10603.6± 
1295.7 
4396.9± 
1210.7 
24 hours 17480± 3079.6 
20229± 
1895.2 
31167± 
2806.3* 
13151.1± 
881.4 
141189.3± 
2342.1 
19503.8± 
4818.7 
 
Table 3F: MCP-1 
Duration 
of 
treatment 
VEC-PT VLC 
Medium 2hr Pulsed Semen Semen Medium 
2hr 
Pulsed 
Semen 
Semen 
2 hours 1.8±0 6.5±4.7 1.8±0 1.8±0 1.8±0 1.8±0 
8 hours 1.8±0 27.1±25.3 19.1±11 1.8±0 6.5±4.7 1.8±0 
24 hours 6.5±4.7 47.8±17.8 259.3±441**** 1.8±0 10.7±8.9 45.3±26.9** 
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Figure	5.	Cytokine	Concentrations	for	VEC-FT	
VEC-FT tissues were treated with Medium, 2 hour pulsed SP, 100% SP, 2 hour pulsed 
semen, 100% semen and N9 for a total duration of 24 hours. Cytokine quantification of the 
tissues was measured by Multiplex Luminex™ Protein Assay at 3 different time points (2,8 
and 24 hours). Each	data	point	represents	mean	of	triplicates ± SEM.		*p≤	0.05,	**p≤0.01,	***p≤0.0005,	****p≤0.0001 
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Medium
2hr Pulsed Semen
Semen
Figure	6.	Cytokine	Concentrations	for	VEC-PT	
VEC-PT tissues were treated with Medium, 2 hour pulsed semen and 100% semen for a total 
duration of 24 hours. Cytokine quantification of the tissues was measured by Multiplex 
Luminex™ Protein Assay at 3 different time points (2, 8 and 24 hours). Each	data	point	represents	mean	of	triplicates ± SEM.	  *p≤0.05,		****p≤0.0001 
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Figure	7.	Cytokine	Concentrations	for	VLC	
VLC tissues were treated with Medium, 2 hour pulsed semen and 100% semen for a total 
duration of 24 hours. Cytokine quantification of the tissues was measured by Multiplex 
Luminex™ Protein Assay at 3 different time points (2,8 and 24 hours). Each	data	point	represents	mean	of	triplicates ± SEM.	 **p≤0.01 	
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Microarray Analysis 
Microarray data from VEC-FT tissues after exposure to SP or pulsed 2hr SP were 
analyzed to identify which pathways were affected. The DAVID analysis was used to 
identify pathways. The analysis showed no up or downregulation of genes involved in 
inflammation, anti-inflammatory cytokines, tissue integrity and cell death which were the 
pathways of interest for this study. Microarray data are reported as log transformed 
relative intensity units (log2).  Genes involved in the pathways of interest were identified. 
None of the genes were significantly different in the treatment vs. medium control 
groups. These were plotted using heat map (Figure 8). 
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Figure 8. Gene Expression of VEC-FT Following Topical Treatment of VEC-FT 
Tissue with SP at 2 and 8 hours  
Three pathways were analyzed closely: inflammatory markers, cell death markers and 
intercellular junctions. Also cytokines of interest were evaluated. No significant differences 
were noted in any of the pathways though some variability was noted in individual gene 
expression (not statistically significant). Up-regulated expressions are marked in green, down-
regulations are reported in red; yellow reflects no difference in expression levels (baseline). 
Left Y axis= names of individual genes, Right Y axis= fold change in expression.  
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DISCUSSION 
Semen is a biologically active fluid, which has been shown to recruit leukocytes 
to the ectocervical mucosa in vivo following sexual intercourse (Sharkey et al. 2012).  In 
vitro studies using ectocervical and vaginal cell lines suggest that seminal plasma causes 
a signaling cascade in treated immortal cell monolayers resulting in a cytokine response 
resembling a proinflammatory state (Grammen et al. 2012; Mianmian et al. 2010; 
Sharkey et al. 2012). It has been hypothesized that this proinflammatory state increases 
the probability of HIV transmission when target cells are attracted to the epithelial layer 
as a result of this increase in cytokine secretion.  
 In the present study, we evaluated whether differentiated vaginal tissue had a 
similar response to semen. We used three in vitro models of fully differentiated human 
vaginal epithelium, available from MatTek Corporation (Ashland, MA):  EpiVaginal-PT 
(VEC-PT), which contains only epithelial cells; EpiVaginal-FT (VEC-FT), which 
contains epithelial cells grown on a fibroblast layer (lamina propria); and EpiVaginal-LC 
(VLC), which contains epithelial cells, fibroblasts and Langerhans cells (LCs). We used 
these three models to determine what cell types produce cytokines following exposure to 
semen, epithelial cells, fibroblast or immune cells (e.g. LCs).  We also compared two 
treatments: exposure of tissue to semen or seminal plasma for 24 hours—similar to 
previous studies—or a 2 hour treatment with semen or seminal plasma followed by a 
wash step (2hr pulse) to simulate the physiological condition of intercourse, where semen 
is rapidly cleared from the vaginal cavity (Graves et al. 1985; Haimovici et al. 1995). 
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 We demonstrated that 24 hour exposure to semen or seminal plasma does not 
alter various aspects of cervicovaginal tissue integrity, including TEER, epithelial 
morphology, and tissue viability.  The EpiVaginalTM tissue was treated with 100% semen 
or seminal plasma with no significant tissue degradation, damage or inflammation. The 
tissue histology demonstrates preserved epithelial morphology during the duration of this 
study independent of the treatment of the tissue. This is consistent with the findings of a 
previous study (Hjelm et al. 2010). These researchers conducted a study to determine if 
human semen or seminal plasma enhanced HIV infection in human vaginal tissue 
explants. Their findings revealed that neither semen nor seminal plasma altered the 
histology of the explants (Kordy et al. 2018). However, this is in contrast with studies 
evaluating the effect of seminal plasma on monolayers of the Ect1 (immortalized 
ectocervical) cell line, which were degraded when exposed to seminal plasma (Sharkey et 
al. 2007; Scott et al. 2016). We attribute this to the difference in tissue structure. The 
superficial stratum corneum of normal vaginal and EpiVaginalTM tissue provides a 
mechanical barrier against luminal contents.  
We next studied the effect of semen treatment on cytokine production by 
EpiVaginalTM tissue.  Previous studies using vaginal cell lines have reported significant 
increases in IL-1β, MCP-1 and IL-8 after 24 hours of exposure to semen or seminal 
plasma (Sharkey et al. 2007; Masson et al. 2016).  We found that semen and seminal 
plasma caused only a modest inflammatory response in EpiVaginalTM tissue with much 
less cytokine production than seen with the cell lines.  When VEC-FT was treated with 
SP, IL-1β was significantly increased in culture supernatants at 24 hours post treatment; 
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however this difference was small (152.1±39 pg/ml vs. 139.4±41.5 pg/ml) and may not 
be physiologically significant.  IL-1β is a pro-inflammatory cytokine that is crucial for 
host-defense responses to infection and injury. It is produced and secreted by a variety of 
cell types from the innate immune system, such as monocytes and macrophages, and is 
also produced by vaginal epithelial cells. Its function has been linked to cell proliferation 
and apoptosis (Dinarello 1996). As a positive control treatment for cytokine production 
we used the spermicide Nonoxynol 9 (N9), which has been shown to stimulate the 
secretion of IL-1α, IL-1β, MCP-1 and IL-8 in EpiVaginalTM cultures (Ayehunie et al. 
2011; Alt et al. 2009). Our study showed a significant elevation of IL-1β, similar to the 
previous study, but no significant increase of MCP-1 or IL-8 production (Ayehunie et al. 
2011, Passmore et al. 2007). This could be due to a difference in formulation. For the 
previous study, a pure chemical solution of N9 was used. In our present study, we used 
Conceptrol, a spermicidal N9 gel formulation available over the counter. The viscous gel 
might have had a barrier effect protecting the underlying tissue and limiting the contact 
with N9. We demonstrated a significantly lower TEER in tissues treated with N9 without 
change in tissue morphology or cytokine production. This might imply that barrier 
properties are compromised early on after tissue exposure but there is a delay in 
observation of other cytotoxic or inflammatory changes. 
We also used VEC-PT and VLC tissues to assess whether the absence of lamina 
propria or the presence of Langerhans cells, respectively, would change the 
responsiveness of the EpiVaginalTM tissues. We noted that there was no alteration in 
morphology or TEER values after treatment with semen or SP in any of the three tissue 
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models. Of all the cytokines tested, the concentration of MCP-1 was significantly 
increased for both VEC-PT and VLC tissues at 24 hours following treatment with semen. 
Monocyte chemoattractant protein 1 (MCP-1), also known as chemokine (C-C motif) 
ligand 2 (CCL2), recruits monocytes, memory T cells, and dendritic cells to the site of 
inflammation.  The expression of this cytokine is often upregulated by tissue injury or 
infection. Also, for VEC-PT, IL-8 was increased at 24 hours following treatment with 
semen. IL-8 is a key mediator associated with inflammation where it plays a role in 
neutrophil recruitment and degranulation. It is also increased by oxidative stress making 
it a parameter in acute inflammation (Harada et al. 1994).  A previous study had shown 
that IL-8 and MCP-1 are upregulated by treatment with seminal plasma in Ect1 cells 
(Sharkey et al. 2007). This increase of MCP-1 in VEC-PT and VLC tissue may be 
physiologically significant because it was quite pronounced (259.3±44.1 pg/ml and 
45.3±26.9 pg/ml).  Increased secretion of MCP-1, which is a chemokine, can increase the 
attraction of HIV target cells, such as CD4+ T cells and macrophages, to the vaginal 
epithelium, increasing the chance of HIV transmission (Mitchell et al. 2014).  
Additionally, we used Microarray analysis to evaluate the effect of SP treatment 
on VEC-FT tissues.  Our data demonstrate that there were no significant effects on cell-
to-cell structural adhesion molecules, inflammatory or cell death markers. However, the 
microarray was only conducted on tissue that was treated for two and eight hours with 
seminal plasma. The shorter exposure was evaluated as it is more physiological with 
previous studies describing rapid decrease of SP or semen markers in the vagina with 
time (Graves et al. 1985; Haimovici et al. 1995).   
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Multiple variables can affect which cytokines are activated in epithelial tissue. 
Sharkey et al. (2007) showed that different concentrations of seminal plasma induced 
different levels of inflammatory mRNA expression. Other experiments have determined 
that inflammation activation is dose and time dependent (Hjelm et al. 2010). Other 
biological factors such as use of hormonal contraceptives and genital tract inflammation 
have been reported to result in changes in vaginal barrier function and immune cell 
composition in explants, which may increase susceptibility to HIV infection. Epithelial 
cells, fibroblasts and immune cells all contribute to the cytokines, chemokines and 
growth factors that are present in the tissue environment of the LFGT (Wira et al. 2014). 
In summary, we have demonstrated that exposure of EpiVaginalTM tissues to 
semen or seminal plasma does not decrease the integrity of the vaginal epithelium. 
Histology and TEER indicate the tissue is still intact after apical treatment of semen 
and/or seminal plasma even after a 24 hour time period. However, semen and seminal 
plasma did cause a slight inflammatory response in EpiVaginalTM tissue. In previous 
studies a robust cytokine response was described and several specific pathways were 
activated (Grammen et al. 2012; Mianmian et al. 2010; Sharkey et al. 2012; Masson et al. 
2015). The suppressed inflammatory response that we saw with differentiated vaginal 
tissue supports our hypothesis that differentiated tissue is less susceptible to 
inflammatory stimulii than cell monolayers, possibly because the stratum corneum (top 
most layer of differentiated epithelium) plays a protective role.  More research needs to 
be conducted by expanding the cytokine profile to better evaluate a pro or anti-
inflammatory response induced by semen in EpiVaginalTM tissue.  
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